Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Omipalisib
Cat. No.:
OB0225LY-0308
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Omipalisib is a small molecule inhibitor targeting the PI3K/mTOR pathway used to study the regulation of signaling pathways.
Synonym:
GSK458; GSK2126458; 1086062-66-9; 2,4-Difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide; 2,4-Difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
CAS No.:
1086062-66-9
Compound CID:
25167777
Formula:
C25H17F2N5O3S
Formula Weight:
505.5
Specification
Relative Density:
1.45 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Omipalisib can be used in tumor biology studies to explore the important role of the PI3K pathway in cell proliferation and survival.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTORC1; p110α; p110β; p110γ; p110δ
Pathways:
PI3K/Akt/mTOR signaling; Autophagy
Plate Number:
AOCL-4
Plate Location:
h10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 98.91 mM
Water Max Solubility:
<1 mg/mL (insoluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
3.705
HBA_Count:
7
HBD_Count:
1
Rotatable Bond:
6
